BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 35395472)

  • 1. The continuing conundrum in oligometastatic breast carcinoma: A real-world data.
    Selvarajan G; Dhanushkodi M; Radhakrishnan V; Kalaiyarasi JP; Murali CS; Ananthi B; Iyer P; Krishnamurthy A; Velusamy S; Ganesarajah S; Sagar TG
    Breast; 2022 Jun; 63():140-148. PubMed ID: 35395472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis.
    Poon I; Erler D; Dagan R; Redmond KJ; Foote M; Badellino S; Biswas T; Louie AV; Lee Y; Atenafu EG; Ricardi U; Sahgal A
    JAMA Netw Open; 2020 Nov; 3(11):e2026312. PubMed ID: 33196810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis.
    Chen X; Chen H; Poon I; Erler D; Badellino S; Biswas T; Dagan R; Foote M; Louie AV; Ricardi U; Sahgal A; Redmond KJ
    Cancer Med; 2021 Sep; 10(18):6189-6198. PubMed ID: 34432390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
    Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
    BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study.
    Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; van Timmeren JE; Kroeze SGC; Mayinger M; Guckenberger M; Andratschke N
    Radiother Oncol; 2022 Mar; 168():256-264. PubMed ID: 35101466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
    Buglione M; Jereczek-Fossa BA; Bonù ML; Franceschini D; Fodor A; Zanetti IB; Gerardi MA; Borghetti P; Tomasini D; Di Muzio NG; Oneta O; Scorsetti M; Franzese C; Romanelli P; Catalano G; Dell'Oca I; Beltramo G; Ivaldi GB; Laudati A; Magrini SM; Antognoni P;
    Lung Cancer; 2020 Mar; 141():1-8. PubMed ID: 31926440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
    Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
    BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.
    Hong JC; Ayala-Peacock DN; Lee J; Blackstock AW; Okunieff P; Sung MW; Weichselbaum RR; Kao J; Urbanic JJ; Milano MT; Chmura SJ; Salama JK
    PLoS One; 2018; 13(4):e0195149. PubMed ID: 29649281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
    Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
    Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and genetic determinants of ovarian metastases from colorectal cancer.
    Ganesh K; Shah RH; Vakiani E; Nash GM; Skottowe HP; Yaeger R; Cercek A; Lincoln A; Tran C; Segal NH; Reidy DL; Varghese A; Epstein AS; Sonoda Y; Chi D; Guillem J; Temple L; Paty P; Hechtman J; Shia J; Weiser M; Aguilar JG; Kemeny N; Berger MF; Saltz L; Stadler ZK
    Cancer; 2017 Apr; 123(7):1134-1143. PubMed ID: 27875625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
    Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
    Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forecasting factors and outcomes in hawkish inflammatory breast carcinoma - A single center data exploration.
    Selvarajan G; Radhakrishnan V; Jayachandran PK; Subramaniam Murali C; Velusamy S; Krishnamurthy A; Iyer P; Ananthi B; Ganesarajah S; Sagar TG
    Cancer Treat Res Commun; 2022; 32():100599. PubMed ID: 35792427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiosurgery in the management of brain metastasis: a retrospective single-center study comparing Gamma Knife and LINAC treatment.
    Tuleasca C; Negretti L; Faouzi M; Magaddino V; Gevaert T; von Elm E; Levivier M
    J Neurosurg; 2018 Feb; 128(2):352-361. PubMed ID: 28338441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
    Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
    Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligometastatic adrenocortical carcinoma: the role of image-guided thermal ablation.
    Veltri A; Basile D; Calandri M; Bertaggia C; Volante M; Porpiglia F; Calabrese A; Puglisi S; Basile V; Terzolo M
    Eur Radiol; 2020 Dec; 30(12):6958-6964. PubMed ID: 32621242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
    Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
    Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients.
    Rii J; Sakamoto S; Yamada Y; Takeshita N; Yamamoto S; Sazuka T; Imamura Y; Nakamura K; Komiya A; Komaru A; Fukasawa S; Nakatsu H; Akakura K; Ichikawa T
    Prostate; 2020 Aug; 80(11):850-858. PubMed ID: 32501559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of locoregional treatment on survival in patients presented with metastatic breast carcinoma.
    Gultekin M; Yazici O; Eren G; Yuce D; Aksoy S; Ozisik Y; Guler N; Yazici G; Hurmuz P; Yildiz F; Altundag K; Gurkaynak M
    Breast; 2014 Dec; 23(6):775-83. PubMed ID: 25201554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
    Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
    J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.